Florida's NeoGenomics has rolled out a number of new diagnostic tests that profile 22 different categories of cancer, including brain, lung, breast, cervix, colorectal, stomach, ovary, soft tissue, thyroid and various types of leukemia tumors.
Belgium's MDxHealth has partnered with generics maker Teva Pharmaceuticals to commercialize its ConfirmMDx for prostate cancer and PredictMDx for glioblastoma tests in Israel.
San Diego's Epic Sciences is working to expand access to its novel cancer diagnostic, joining forces with global giant LabCorp to make the test available to European drug developers.
New genes identified by scientists at the University of Louisville in Kentucky may indicate a person's predisposition to excess abdominal fat, which can be an indicator of more serious health conditions, such as cardiovascular disease, Type 2 diabetes and cancer.
Researchers in Singapore and China are putting into play a new biomarker that appears to help spot a common form of esophageal cancer. It also enables clinicians to identify patients with the disease facing dicey survival prospects.
Knowing how to preserve human embryonic stem cells in their pluripotent state until they are needed will help scientists better harness these cells for use in a variety of therapies. Now researchers have identified a gene receptor and signaling pathway that plays an essential role in preserving hESCs in an undifferentiated state.
A newly discovered biomarker may help identify patients who will respond best to treatment as well as present a target for new drugs to help prevent metastasis, according to research published in Nature Communications.
Blueprint Medicines has completed a $25 million round of Series B financing to pursue its patient-focused vision of developing tailored, genomic-specific cancer treatments.
Lung cancer spreads quickly, which helps it claim more lives each year than any other cancer worldwide and makes early detection key. Now, two companies have teamed up to bring a diagnostic test to some of the countries that need it most.
Johnson & Johnson's global hunt for new technologies has led it to a fledgling biotech working on a new approach to triggering an immune system attack, as well as stopping one.